Medivation Inc (MDVN)
Quote as of 10:09 AM ET 07/29/2010 (NASDAQ GM)
| Last: 9.36 |
Change: ($0.08) |
Percent Change: -0.85 |
Volume: 12,438 |
Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company?s product candidates in clinical development are dimebon (latrepirdine), which is in Phase III development for the treatment of Alzheimer?s disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer. Its dimebon program is partnered with Pfizer Inc. (Pfizer) and its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas).
Latest News
8:00:00 AM 5/3/2010
Medivation Announces First Quarter 2010 Financial Results Teleconference and Webcast on May 10, 2010
SAN FRANCISCO, May 3, 2010 /PRNewswire via COMTEX/ --
Medivation, Inc. (MDVN) today announced that it will host a teleconference and webcast with management to discuss first quarter 2010 financial results and provide a general business update on May 10, 2010, at 4:30 p.m. Eastern Time. A press release for the first quarter ended March 31, 2010 will be released after markets close on May 10, 2010.
3:30:00 PM 4/13/2010
Baxter drug shows promise in Alzheimer's
BOSTON (MarketWatch) - A blood product marketed by Baxter International is showing considerable promise in treating Alzheimer's disease, according to a study unveiled by researchers on Tuesday.
10:51:00 AM 3/4/2010
CombinatoRx rebounds; drug indexes flat
BOSTON (MarketWatch) -- CombinatoRx Inc. was the notable mover among the small-cap issues early Thursday, with shares of the biotech group gaining sharply after diving almost 10% during the previous session.